What development phase is menthyl salicylate in?

menthyl salicylate is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

menthyl salicylate

FDA-approved active Quality 6/100

Menthyl salicylate is a marketed drug that releases salicylic acid, leveraging its anti-inflammatory and pain-relieving properties. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk is the loss of exclusivity post-patent expiry, which could erode market share and revenue.

At a glance

Generic name	menthyl salicylate
Drug class	menthyl salicylate
Therapeutic area	Pain
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

menthyl salicylate CI brief — competitive landscape report
menthyl salicylate updates RSS · CI watch RSS
portfolio CI